102D-6

Primary Objective: To conduct a preliminary comparison of the pharmacokinetic profiles of a 20 mg 13C-102D-6 dry suspension and a 20 mg mabaloxavir tablet in healthy Chinese male adults following a single oral dose with a high-fat meal and a low-fat meal. Secondary Objective: To evaluate the safety of the 13C-102D-6 dry suspension in healthy Chinese male adults following a high-fat meal and a low-fat meal, and to compare the safety of the 13C-102D-6 dry suspension with that of the mabaloxavir tablet.

Main objective: To evaluate and compare the pharmacokinetic characteristics of a single simultaneous oral administration of 20 mg 13C-102D-6 dry suspension and 20 mg mabaloxavir tablets or 20 mg 102D-6 dry suspension in healthy subjects under fasting conditions, to evaluate the relative bioavailability of 13C-102D-6 dry suspension and mabaloxavir tablets, the bioequivalence of 13C-102D-6 dry suspension and 102D-6 dry suspension, and to bridge the relative bioavailability of 102D-6 dry suspension to mabaloxavir tablets through 13C-102D-6 dry suspension. Secondary objectives: 1. To evaluate the safety and tolerability of a single oral dose of 13C-102D-6 dry suspension and 102D-6 dry suspension in healthy Chinese adult subjects, and compare them with mabaloxavir tablets; 2. To provide data support for the subsequent study of the dose design of 102D-6 and the bioequivalence, efficacy and safety bridge with mabaloxavir tablets; 3. To compare the plasma metabolites of 102D-6 dry suspension and mabaloxavir tablets.